505(b)(2) Development
A faster, lower-risk route to differentiated pharmaceutical products — leveraging existing safety and efficacy data to reach the US market with greater efficiency.
An efficient pathway for innovative drug products
The 505(b)(2) pathway enables differentiated pharmaceutical products to reach the US market using existing safety and efficacy data — reducing development cost, risk and time-to-market.
Enventor supports product assessment, RLD identification, data gap analysis and end-to-end development to position your product for a successful 505(b)(2) submission. A similar regulatory approval route in Europe is the Hybrid procedure based on Article 10 of Directive 2001/83/EC.
Benefits of the 505(b)(2) pathway
The 505(b)(2) pathway offers pharmaceutical companies a strategic advantage by reducing the time and financial investment typically required for a conventional full NDA — bypassing many nonclinical studies and extensive safety and efficacy testing.
Lower risk
Builds on previously approved drugs and existing safety/efficacy data.
Faster, lower-cost development
Fewer studies required, reducing both timelines and expense.
Market exclusivity
Qualifies for 3, 5, or 7 years of market exclusivity depending on the program.
Competitive advantage
Differentiated products that alleviate competitive pressure with a streamlined route.
Integrated 505(b)(2) development support
Pathway Assessment
- Assessment of product suitability for 505(b)(2)
- Identification of reference listed drug (RLD)
- Data gap and development requirement analysis
- Regulatory-aligned development planning
Formulation & Analytical
- Formulation development support
- Analytical method development & validation
- Comparative dissolution and characterization
- Differentiation strategy (strength, route, indication)
Stability & CMC Data
- Stability studies under ICH conditions
- CMC data generation aligned to submission needs
- Quality module documentation
- Specification and control strategy development
Bridging Strategy
- Bioequivalence / bridging study strategy support
- Clinical pharmacology strategy alignment
- Reliance on RLD safety/efficacy data
- Regulatory submission readiness
Explore a 505(b)(2) program with Enventor
From RLD identification to submission readiness — backed by science, quality, and regulatory expertise.
Get in touch